Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia

Key facts

Sponsor

Fred Hutchinson Cancer Center

Principal Investigator

David Maloney

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Intervention

Cyclosporine(drug)

Enrollment

21 enrolled

Eligibility

21 years · All sexes

Timeline

2003 – 2010

Study locations (3)

• Veterans Administration Center-Seattle, Seattle, Washington, United States
• Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
• University of Torino, Torino, Italy

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for B-cell prolymphocytic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT05418088
  Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
  Sumithira Vasu
• ACTIVE NOT RECRUITINGPHASE1NCT02153580
  Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
  City of Hope Medical Center
• ACTIVE NOT RECRUITINGPHASE2NCT02007044
  Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
  M.D. Anderson Cancer Center
• ACTIVE NOT RECRUITINGPHASE2NCT01589302
  PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
  Kami Maddocks, MD

See all trials for B-cell prolymphocytic leukemia →